世界の制吐剤市場2021-2031:薬剤別(抗ヒスタミン薬、セロトニン受容体拮抗薬、ドーパミン受容体拮抗薬、ニューロキニン受容体拮抗薬、抗コリン薬、その他)、用途別、流通チャネル別

【英語タイトル】Antiemetics Market By Drug Type (Antihistamines, Serotonin Receptor Antagonists, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Anticholinergics, Other Drug Types), By Application (Chemotherapy, Post Operative Surgery, Pregnancy and Gatroenteritis, Other Applications), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料(ALD23FB243)・商品コード:ALD23FB243
・発行会社(調査会社):Allied Market Research
・発行日:2022年11月
・ページ数:260
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single UserUSD5,730 ⇒換算¥848,040見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥954,600見積依頼/購入/質問フォーム
Enterprise UserUSD9,600 ⇒換算¥1,420,800見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Allied Market Research社の本調査資料では、2021年に2,251.68百万ドルであった世界の制吐剤市場規模が、2031年までに4,061.36百万ドルに成長し、2022年から2031年の間に年平均6.1%で拡大すると予想しています。本書は、制吐剤の世界市場を総合的に分析し、市場実態を明らかにするとともに、将来を展望したレポートです。イントロダクション、エグゼクティブサマリー、市場概要、薬剤別(抗ヒスタミン薬、セロトニン受容体拮抗薬、ドーパミン受容体拮抗薬、ニューロキニン受容体拮抗薬、その他)分析、用途別(化学治療、術後管理、妊娠・胃腸炎、その他)分析、流通チャネル別(小売薬局、病院薬局、オンライン薬局)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ)分析、企業状況、企業情報などの項目を掲載しています。本書には、GlaxoSmithKline Plc、Sanofi、Novartis AG、Pfizer Inc、Merck & Co. Inc、Dr. Reddy’s Laboratories Ltd、Cipla、Johnson & Johnson、Torrent Pharmaceuticals Ltd、Acacia Pharma Groupなどの企業情報が含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の制吐剤市場規模:薬剤別
- 抗ヒスタミン薬の市場規模
- セロトニン受容体拮抗薬の市場規模
- ドーパミン受容体拮抗薬の市場規模
- ニューロキニン受容体拮抗薬の市場規模
- その他の市場規模
・世界の制吐剤市場規模:用途別
- 化学治療における市場規模
- 術後管理における市場規模
- 妊娠・胃腸炎における市場規模
- その他における市場規模
・世界の制吐剤市場規模:流通チャネル別
- 小売薬局チャネルの市場規模
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の制吐剤市場規模:地域別
- 北米の制吐剤市場規模
- ヨーロッパの制吐剤市場規模
- アジア太平洋の制吐剤市場規模
- 中南米・中東・アフリカの制吐剤市場規模
・企業状況
・企業情報

The global antiemetics market was valued at $2,251.68 million in 2021, and is projected to reach $4,061.36 million by 2031, registering a CAGR of 6.1% from 2022 to 2031.

Emesis also known as vomiting or throwing up refers to involuntary, forceful expulsion of substances out of the stomach through mouth or sometimes through nose and medications used to stop these involuntary expulsions are known as antiemetics. Seasickness and other motion sicknesses, early pregnancy, intense pain, exposure to chemical toxins, emotional stress (fear), gallbladder disease, food poisoning and indigestion are some of the common causes associated with emesis. In addition, chemotherapy, gastroenteritis, general anesthesia, intestinal obstruction, migraine and others serious ailments may also lead to nausea and vomiting in the patient.

Rise in number of chemotherapies is one of the major driving factor for the growth of the antiemetics market. According to the American Cancer Society (ACS), 609,360 cancer deaths and 1.9 million new cases are anticipated to occur in the United States in 2022. The rate of cancer fatalities for both men and women combined has declined to 32% from its high in 1991 to 2019. The surge in adoption of various cancer therapies by the patient, including chemotherapy and radiation therapy, is mainly responsible for this decline in death rates. The use of chemotherapy and radiation therapy is expected to boost demand for antiemetic medications because these treatments are associated with adverse effects like nausea and vomiting. Thus, it is anticipated that a high prevalence of cancer cases and extensive use of chemotherapy as the treatment option will fuel the global antiemetics market during the forecast period.

Furthermore, rise in funding by governments of various countries and private organizations to initiate manufacturing units are expected to boost the market growth. Also, the government organizations of the respective countries are proving funds to carry out the research and development for the new molecules, which boost the growth of the market in that region. In addition, acquisition and partnerships by the key market players are the boosting factors for the market. These key strategies are mainly adopted by the key market players to expand their business and their product portfolio, which leads to increase in sales of the company, along with the growth of the market.

Additionally, the occurrence of gastroenteritis, often known as stomach flu, contributes to market growth. Gastroenteritis is an inflammation of the stomach and intestines that is typically brought on by viruses, bacteria, or parasites infected food or water. It produces nausea, fever, cramps, nausea, and headaches in addition to stomach discomfort and cramping. Additionally, Norovirus is a prominent source of gastroenteritis and foodborne disease outbreaks in the United States, which causes nausea and vomiting in the patients. This prevalence of Norovirus infection, demands for the antiemetics treatment medications, which is driving up sales of antiemetics in this region and boosting market growth overall.

However, less awareness about antiemetic drugs among the population hinders growth of the market. In some cases, the strength, dose and drug class of the prescribed antiemetics may lead to the severe condition in the patients, which demands for the proper knowledge regarding the medicine and its pharmacology, which can act as a restraint to the antiemetics market. On the contrary, rise in research and development activities by key market players and increase in healthcare expenditure has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the antiemetics market. Also, the presence of raw material in the developing regions such as Asia and LAMEA, provides lucrative opportunities for the market players to invest in this region.

The global antiemetics market is segmented on the basis of drug type, application, distribution channel, and region. By drug type, the market is categorized into antihistamines, serotonin receptor antagonists, dopamine receptor antagonists, neurokinin receptor antagonists, anticholinergics, and others. Depending on application, it is segmented into chemotherapy, post-operative surgery, pregnancy and gastroenteritis, and others. On the basis distribution channel, it is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global Antiemetics market are Abbott Laboratories, Benuvia Therapeutics Inc., Cipla, Dr. Reddy’s Laboratories Ltd, Eisai Co. Ltd, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer In. and Teva Pharmaceuticals among others.
 
Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antiemetics market analysis from 2021 to 2031 to identify the prevailing antiemetics market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the antiemetics market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global antiemetics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type
● Antihistamines
● Serotonin Receptor Antagonists
● Dopamine Receptor Antagonists
● Neurokinin Receptor Antagonists
● Anticholinergics
● Other Drug Types

By Application
● Chemotherapy
● Post Operative Surgery
● Pregnancy and Gatroenteritis
● Other Applications

By Distribution Channel
● Retail Pharmacies
● Hospital Pharmacies
● Online Pharmacies

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest Of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ Australia
○ South Korea
○ Rest Of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest Of LAMEA

● Key Market Players
○ GlaxoSmithKline Plc
○ Sanofi
○ Novartis AG
○ Pfizer Inc
○ Merck & Co. Inc
○ Dr. Reddy’s Laboratories Ltd
○ Cipla
○ Johnson & Johnson
○ Torrent Pharmaceuticals Ltd
○ Acacia Pharma Group

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: ANTIEMETICS MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Antihistamines
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Serotonin Receptor Antagonists
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Dopamine Receptor Antagonists
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Neurokinin Receptor Antagonists
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Anticholinergics
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
4.7 Other Drug Types
4.7.1 Key market trends, growth factors and opportunities
4.7.2 Market size and forecast, by region
4.7.3 Market analysis by country
CHAPTER 5: ANTIEMETICS MARKET, BY APPLICATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Chemotherapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Post Operative Surgery
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Pregnancy and Gatroenteritis
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Other Applications
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: ANTIEMETICS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Retail Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Hospital Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: ANTIEMETICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Type
7.2.3 North America Market size and forecast, by Application
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Type
7.2.5.1.2 Market size and forecast, by Application
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Type
7.2.5.2.2 Market size and forecast, by Application
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Type
7.2.5.3.2 Market size and forecast, by Application
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Type
7.3.3 Europe Market size and forecast, by Application
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Type
7.3.5.1.2 Market size and forecast, by Application
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Type
7.3.5.2.2 Market size and forecast, by Application
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Type
7.3.5.3.2 Market size and forecast, by Application
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Type
7.3.5.4.2 Market size and forecast, by Application
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Type
7.3.5.5.2 Market size and forecast, by Application
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Type
7.3.5.6.2 Market size and forecast, by Application
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Type
7.4.3 Asia-Pacific Market size and forecast, by Application
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Market size and forecast, by Drug Type
7.4.5.1.2 Market size and forecast, by Application
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 Japan
7.4.5.2.1 Market size and forecast, by Drug Type
7.4.5.2.2 Market size and forecast, by Application
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Type
7.4.5.3.2 Market size and forecast, by Application
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Type
7.4.5.4.2 Market size and forecast, by Application
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Type
7.4.5.5.2 Market size and forecast, by Application
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Type
7.4.5.6.2 Market size and forecast, by Application
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Type
7.5.3 LAMEA Market size and forecast, by Application
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Type
7.5.5.1.2 Market size and forecast, by Application
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Type
7.5.5.2.2 Market size and forecast, by Application
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Type
7.5.5.3.2 Market size and forecast, by Application
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Type
7.5.5.4.2 Market size and forecast, by Application
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 GlaxoSmithKline Plc
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Sanofi
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Novartis AG
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Pfizer Inc
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Merck & Co. Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Dr. Reddy’s Laboratories Ltd
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Cipla
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Johnson & Johnson
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Torrent Pharmaceuticals Ltd
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Acacia Pharma Group
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments



★調査レポート[世界の制吐剤市場2021-2031:薬剤別(抗ヒスタミン薬、セロトニン受容体拮抗薬、ドーパミン受容体拮抗薬、ニューロキニン受容体拮抗薬、抗コリン薬、その他)、用途別、流通チャネル別] (コード:ALD23FB243)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の制吐剤市場2021-2031:薬剤別(抗ヒスタミン薬、セロトニン受容体拮抗薬、ドーパミン受容体拮抗薬、ニューロキニン受容体拮抗薬、抗コリン薬、その他)、用途別、流通チャネル別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆